- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04896164
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting
Phase III Randomized, Double Blind, Placebo Controlled Study of Curcumin to Reduce Mucositis in Autologous Transplant Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mucositis is an inevitable side-effect of intensive conditioning therapy used for hematopoietic stem cell transplantation and affects the quality of life of patients undergoing transplant. The incidence of oral mucositis (WHO grades 3/4 ) with certain myeloablative conditioning regimens has been reported in up to 90% with range of severe mucositis (WHO grade 3/4) from 10 to 78%. Pro-inflammatory cytokines such as IL-1, IL-6, IL-8, IL-17, TNF-α, TGF-B, IFN-γ and certain prostaglandins play a central role in its pathogenesis. Transcription factors such as NF-kappa B, modify the genetic expression of these cytokines and enzymes which are critical in producing tissue damage.
A number of agents and methods have been investigated to prevent or reduce mucositis in transplant setting. Some of them are amifostine, caphasol, palifermin, cryotherapy, chlorhexidine, glutamine, GM-CSF, histamine, misoprostol, laser therapy and traumeel, but only palifermin and cryotherapy have shown significant benefit.
Curcumin, polyphenol derivative with low toxicity profile, is commonly used in India for its anti-inflammatory actions. Curcumin inhibits various inflammatory cytokines through inhibition of Nuclear Factor Kappa- β. It is derived from the plant Curcuma longa. In vitro studies have shown potent anti-inflammatory activity at concentrations of 1 umol/L.
The investigators conducted the first study evaluating the role of curcumin on oral mucositis in transplant setting. In this pilot study (n=40), patients who received curcumin lozenges (n=30) had decreased levels of salivary TGF-β, IL-17 and serum PGE2 compared to patients who did not receive the curcumin lozenges (n=10). Patients who received the curcumin lozenges had higher levels of serum IL-8 which is a prohealing cytokine. The incidence of grade 3 and 4 oral mucositis and diarrhea was less in those who received curcumin lozenges. Curcumin lozenges were also well tolerated and none of the 30 patients who were administered curcumin developed any treatment related grade 3/4 toxicity. This encouraging data is the basis of the current phase III randomized study comparing curcumin lozenges to placebo, to assess the ability of curcumin to reduce the incidence and duration of oral mucositis in patients undergoing autologous bone marrow transplantation.
The formulation being used is a Solip Lipid Curcumin microParticle (SLCP). The formulation is developed by Pharmanza Herbals Pvt. Ltd., Gujarat, India. Gota et al reported a phase I clinical trial of SLCP where upto 4 grams of the formulation containing 20-30% curcumin was evaluated for safety and pharmacokinetics in patients with high-risk osteosarcoma (Ref). The SLCP formulation showed oral bioavailability of curcumin with linear pharmacokinetics. Average peak plasma concentration of 41 ng/mL was observed at the highest dose level of 4g. All doses were well tolerated and no adverse events were observed. Based on these observations (on safety and bioavailability), and the reported anti-inflammatory properties of curcumin, it was envisaged that it could be potentially useful for the prophylaxis and treatment of oral mucositis following high-dose chemotherapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Navin Khattry, MD, DM
- Phone Number: 5034 022-27405000
- Email: nkhattry@gmail.com
Study Locations
-
-
Maharashtra
-
Navi Mumbai, Maharashtra, India, 410210
- Recruiting
- Tata Memorial Centre
-
Contact:
- Navin Khattry, MD, DM
- Phone Number: 5034 022-24705000
- Email: nkhattry@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 18 years and above.
- Patients who give written informed consent
- Patients with performance status - 0,1 or 2 (ECOG scale)
Patients receiving any of the following high dose chemotherapy regimens for autologous transplant in any indicated malignant disease.
- Melphalan- 200 mg/m2 or more (MEL-200 mg/m2)
- Busulfan and Melphalan (BuMEL)
- Carmustine (BCNU), Etoposide, Cytosine Arabinoside and Melphalan ( BEAM)
- Patients who have creatinine clearance > 50 ml/min
- Patients with serum bilirubin levels < 2mg/dl. and serum liver enzymes (ALT or AST or both) lesser than 5 times the upper limit of normal value.
Exclusion Criteria:
- Patients who are on NSAIDs, aspirin, antioxidants or systemic steroids for more than 3 months and the last dose taken within the last one week.
- Patients being treated for active infection at the time of starting high dose chemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational arm
Patients in the investigational arm will receive curcumin lozenges (4 gm BD containing 400 mg curcumin BD) as prophylaxis from two days prior to receiving high dose chemotherapy .
|
Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD.
Formulation is Solid Lipid Curcumin Particle (SLCP).
Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
Other Names:
|
Placebo Comparator: Control arm
patients in the control arm will receive matching placebo lozenges from two days prior to receiving high dose chemotherapy
|
Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of grade 3 and 4 oral mucositis
Time Frame: Day+28
|
In both groups, patients will be evaluated clinically for oral mucositis.
The incidence of grade III/IV oral mucositis will be recorded as per WHO grading criteria.
|
Day+28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of any grade of oral mucositis.
Time Frame: Day+28
|
In both groups, patients will be evaluated clinically for oral mucositis and grade will be recorded as per WHO grading criteria.
|
Day+28
|
Duration of grade 3 and 4 oral mucositis in both groups
Time Frame: Day+28
|
In both groups, duration of oral mucositis will be recorded.
|
Day+28
|
Incidence of use of Total Parenteral Nutrition
Time Frame: Day+28
|
Incidence of use of Total Parenteral Nutrition in both groups.
|
Day+28
|
Duration of use of Total Parenteral Nutrition
Time Frame: Day+28
|
The duration of use of total parenteral nutrition will be recorded in both groups.
|
Day+28
|
Serum TNF alpha AUC (0-14)
Time Frame: Day+14
|
This will be calculated using serum TNF alpha levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary TNF alpha AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary TNF alpha levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Interleukin 1 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Interleukin 1 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Interleukin 1 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Interleukin 1 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Interleukin 6 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Interleukin 6 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Interleukin 6 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Interleukin 6 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Interleukin 8 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Interleukin 8 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Interleukin 8 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Interleukin 8 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Interleukin 17 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Interleukin 17 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Interleukin 17 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Interleukin 17 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum TGF-beta AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum TGF-beta levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary TGF-beta AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary TGF-beta levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Interferon gamma AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Interferon gamma levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Interferon gamma AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Interferon gamma levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Serum Prostaglandin E2 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Serum Prostaglandin E2 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Salivary Prostaglandin E2 AUC (0-14)
Time Frame: Day+14
|
This will be calculated using Salivary Prostaglandin E2 levels measured at baseline, day 0, then Monday, Wednesday and Friday till day +14.
Using these values, AUC (0-14) will be calculated using linear trapezoidal model.
|
Day+14
|
Plasma curcumin AUC (0-12 hr)
Time Frame: Up to 12 hours from 1st dose
|
This will be done using plasma curcumin levels measured within 1 hr of dosing, 0.5-3 hr, 4-6 hr, and 8 - 12 hr post dose on day 7 of starting curcumin or placebo.
|
Up to 12 hours from 1st dose
|
Plasma Bis-demethoxycurcumin AUC (0-12 hr)
Time Frame: Up to 12 hours from 1st dose
|
This will be done using plasma Bis-demethoxycurcumin levels measured within 1 hr of dosing, 0.5-3 hr, 4-6 hr, and 8 - 12 hr post dose on day 7 of starting curcumin or placebo.
|
Up to 12 hours from 1st dose
|
Plasma demethoxycurcumin AUC (0-12 hr)
Time Frame: Up to 12 hours from 1st dose
|
This will be done using plasma demethoxycurcumin levels measured within 1 hr of dosing, 0.5-3 hr, 4-6 hr, and 8 - 12 hr post dose on day 7 of starting curcumin or placebo.
|
Up to 12 hours from 1st dose
|
Duration of use of analgesics for pain due to oral mucositis
Time Frame: Day+28
|
Duration of use of analgesics for pain due to oral mucositis in both groups will be recorded.The severity of pain will be measured using the visual analog pain scale.
|
Day+28
|
Incidence of grade 3 and 4 nausea
Time Frame: Day+28
|
In both groups, grade of nausea will be recorded as per CTCAE v 4.0 grading criteria.
|
Day+28
|
Incidence of grade 3 and 4 vomiting
Time Frame: Day+28
|
In both groups, grade of vomiting will be recorded as per CTCAE v 4.0 grading criteria.
|
Day+28
|
Incidence of grade 3 and 4 diarrhea
Time Frame: Day+28
|
In both groups, grade of diarrhea will be recorded as per CTCAE v 4.0 grading criteria.
|
Day+28
|
Duration of hospital stay
Time Frame: From date of hospital admission until date of hospital discharge assessed up to day +28
|
The duration of hospital stay will be recorded in both groups.
|
From date of hospital admission until date of hospital discharge assessed up to day +28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Navin Khattry, MD, DM, Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Stomatognathic Diseases
- Mouth Diseases
- Mucositis
- Stomatitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- 900503
- CTRI/2018/09/015846 (Registry Identifier: Clinical Trials Registry - India (CTRI))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Mucositis (Ulcerative)
-
Cairo UniversityCompletedOral Mucositis (Ulcerative)Egypt
-
MuReva Phototherapy Inc.RecruitingHead and Neck Cancer | Oral Mucositis (Ulcerative) | Oral Mucositis (Ulcerative) Due to Radiation | Oral Mucositis (Ulcerative) Due to Antineoplastic TherapyUnited States
-
Tata Memorial CentreCompletedOral Mucositis (Ulcerative)India
-
Salma Hesham ElhoufiRecruitingOral Mucositis (Ulcerative) Due to Radiation | Radiation-Induced Mucositis | Radiation MucositisEgypt
-
Shahid Beheshti University of Medical SciencesUnknownOral Mucositis (Ulcerative) Due to RadiationIran, Islamic Republic of
-
Cairo UniversityNational Cancer Institute (NCI)UnknownOral Mucositis (Ulcerative) Due to Antineoplastic TherapyEgypt
-
Hams Hamed AbdelrahmanAlexandria UniversityCompletedOral Mucositis (Ulcerative) Due to RadiationEgypt
-
Cairo UniversityNational Cancer Institute, EgyptUnknownOral Mucositis (Ulcerative) Due to Antineoplastic TherapyEgypt
-
Chinese University of Hong KongNot yet recruitingHead and Neck Neoplasms | Oral Mucositis (Ulcerative) Due to Radiation | Chinese Medicine Oral RinseHong Kong
-
Mansoura UniversityRecruitingOral Mucositis (Ulcerative) Due to RadiationEgypt
Clinical Trials on Curcumin Lozenges
-
University of HelsinkiThe University Pharmacy, HelsinkiCompletedRespiratory Tract Infections | Common ColdFinland
-
John HaleRecruiting
-
Jordan University of Science and TechnologyActive, not recruitingWhite Spot LesionJordan
-
University of ZagrebBioGaia ABUnknown
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.CytoPharm, Inc.Completed
-
A. Vogel AGCompletedRespiratory Tract Infection Viral | TonsillopharyngitisBulgaria
-
Tata Memorial CentreCompletedOral Mucositis (Ulcerative)India
-
Nutrin GmbHCompletedPharyngitis | Sore Throat | Throat InfectionIndia
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.Texas Tech University Health Sciences CenterTerminatedPulmonary Disease, Chronic Obstructive | Cough | Pulmonary FibrosisUnited States